Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma, Inc. (Nasdaq: IMMX) reports promising data on IMX-110 in combination with anti-PD-1, achieving a 63-day median survival in a KPC pancreatic cancer mouse model, compared to the historical median of 42 days from a standard 4-drug regimen. This significant result underlines the potential of IMX-110, which is set to enter a Phase 1b/2a clinical trial with BeiGene's tislelizumab in advanced solid tumors in 2022. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, positioning it well for future clinical advancements.
Immix Biopharma (Nasdaq: IMMX) announced positive interim results from its Phase 1b/2a clinical trial of IMX-110 for soft tissue sarcoma (STS), reporting 100% of patients completed planned treatment cycles without drug-related interruptions. This contrasts with the historical completion rates of 43-67% for existing STS treatments. IMX-110 holds orphan drug and rare pediatric disease designations from the FDA, which may facilitate faster regulatory review. The STS market is projected to grow from $3 billion to $6.5 billion by 2030.
Immix Biopharma reported promising results for its lead candidate IMX-110, demonstrating a 50% response rate in a study involving first-line-therapy-resistant soft tissue sarcoma (STS) mice, outperforming the standard treatment doxorubicin’s 0% response rate. This candidate is positioned in a lucrative market projected to grow from $2.9 billion in 2019 to $6.5 billion by 2030. Additionally, IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, which could expedite its development and approval process.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced the IMMX Investors Day Event on February 1, 2022. An online Q&A platform is open for shareholders to submit questions until January 20. The live event will be webcasted on the Investor Relations website, and a replay will be provided afterward. ImmixBio specializes in Tissue Specific Therapeutics (TSTx) for oncology and immuno-dysregulated diseases, with a proprietary platform that enhances drug delivery. Investors are encouraged to participate and engage with management during this event.
Immix Biopharma (Nasdaq: IMMX) has received Rare Pediatric Disease Designation from the FDA for IMX-110, aimed at treating rhabdomyosarcoma, a life-threatening pediatric cancer. This designation may allow the company to obtain a Priority Review Voucher (PRV) upon marketing approval, potentially valued between $67 million to $350 million. IMX-110 is currently in a Phase 1b/2a clinical trial and has shown promising data, including a median progression-free survival of four months with no severe drug-related adverse events.
Immix Biopharma, Inc. (Nasdaq: IMMX) has successfully closed its initial public offering (IPO) of 4.2 million shares at $5.00 per share, raising $21 million. An additional 630,000 shares may be purchased by underwriters for over-allotments. The funds will support clinical trials for IMX-110 and other IND-enabling studies. The shares began trading on the Nasdaq Capital Market on December 16, 2021. ThinkEquity acted as the book-running manager for the offering. The company focuses on developing Tissue Specific Therapeutics for oncology and immuno-dysregulated diseases.
Immix Biopharma, Inc. (Nasdaq: IMMX) has priced its initial public offering (IPO) at $5.00 per share, aiming to raise $21 million before expenses. The offering consists of 4,200,000 shares, with an additional 630,000 shares available for overallotments. Trading on Nasdaq is set to begin on December 16, 2021, with the offering closing on December 20, 2021. Proceeds will fund a Phase 2a trial for IMX-110 in soft tissue sarcoma, a Phase 1b trial, and other corporate purposes. ThinkEquity is the sole book-running manager for this offering.